Bayer: Out of Trouble Come Opportunities
Bayer's respiratory diseases spin-out Aerovance shows how new opportunities are springing out of Europe's mid-sized firms, many of which are in transition.
You may also be interested in...
Financing will fund Phase IIb studies and formula enhancements for uncontrolled asthma compound; expects to partner drug in 2010.
VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.
Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas